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Endothelial cell seeding of prosthetic surfaces ha  been proposed as a technique to improve the patency of vascular grafts 
following arterial reconstruction. The introduction of specific recombinant DNA into seeded endothelial cells mayenhance 
the anti-thrombogenic nature of th endothelial-blood interface with a consequent reduction in graft thrombosis. However, 
the successful use of genetically modified endothelial cells in the eeding process relies on the cells retaining normal function 
in terms of cellular replication, attachment and secretion of anti-thrombotic mediators. Successful genetic manipulation of 
human endothelial cells has been accomplished by viral and chemical methods. 
Aim: To study the functional characteristics ofelectrontransfected endothelial cells. 
Methods and results: Endothelial cells were electro-transfected with hetest plasmid pTCF at a transfection efficiency of 
10% utilising a single electric pulse with an electric field of 1000 volts/cm and a time constant of 12.8ms. 
The functional status of transfected endothelial cells was then compared with a control endothelial cell population. There 
were no significant differences in r plication (p = 0.76), attachment (p = 0.43), basal (p = 0.89) or stimulated (p = 0.11) 
prostacyclin release between transfected cells as compared with control endothelial cells. 
Conclusion: Genetically modified cells are functionally normal, and may be used in endothelial cell seeding of prosthetic 
vascular surfaces. 
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Introduction 
The endothelial cell is a particularly attractive target 
for gene transfer as it occupies an important strategic 
position by virtue of its intimate contact with the 
bloodstream. Vascular diseases are an obvious and 
attractive target for gene therapy due to their high 
incidence and prevalence, 1 and the luminal release of 
exogenous proteins by genetically modified endothe- 
lium has been proposed as a means by which 
thrombosis, platelet aggregation, vasoconstriction a d 
smooth muscle cell proliferation following arterial 
reconstruction could be treated. 2 Damage or loss of the 
endothelial surface which occurs during all forms of 
arterial reconstruction may lead to thrombosis and 
restenosis. 3~ The introduction of anti-thrombotic and 
anti-mitogenic genes into the arterial wall during 
these procedures could potentially be utilised to 
prevent early thrombosis and intimal hyperplasia. 5'6
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The plasmid pTCF 7 conferring neomycin resis- 
tance has been successfully introduced into human 
umbilical vein endothelial cells by a physical method 
known as electroporation. 8 This procedure involves 
the application of an electric field across a cell leading 
to polarisation of the cell membrane. 9 A potential 
difference develops, which if large enough to exceed a
critical threshold, will lead to reversible membrane 
breakdown and the formation of pores large nough 
to allow the transmembrane passage of macromole- 
cules such as DNA. 1°-13 The critical parameters for 
successful electro-transfection are the electric field and 
the time constant (duration of the electric discharge). 
We have previously optimised the transfer of the 
plasmid pTCF into endothelial cells by electroporation 
using a single electric pulse with an electric field of 
1000 volts/cm and a time constant of 12.8ms) 4 
The seeding of transfected endothelial cells has 
been proposed as a technictue to improve the patency 
of vascular prostheses, 15-q° but it is critical that these 
cells retain functional normality. We therefore studied 
the functional characteristics of electro-transfected 
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endothelial cells by examining their attachment to 
ePTFE grafts, their growth rates and their release of 
prostacyclin. 
Materials and Methods 
Endothelial ceil harvest and culture 
Endothelial cells were harvested under sterile condi- 
tions from human umbilical veins within 24 h of 
delivery, using a method modified from Jaffe et al. 17 
Identification of endothelial cells was confirmed by 
their characteristic obblestone appearance and by 
staining with rabbit anti-human von Willebrand Fac- 
tor antibody (Dakopatts, Glostrup, Denmark) and a 
mouse monoclonal antibody specific for thrombomo- 
dulin (QB-END/40.1 - Quantum Biosystems Ltd, 
U.K.). Cells were cultured in T25, 80 and 175 tissue 
culture flasks (Nunclon, Kamstrup, Denmark) in 
Medium 199 (ICN, High Wycombe, U.K.) containing 
20% fetal calf serum (FCS - Sera Lab, Lot 001010, U.K.), 
100U/ml streptomycin, 100U/ml penicillin (NBL, 
Northumbria, U.K.) at 37°C, in a 95% air and 5% CO2 
atmosphere. Endothelial cells were passaged at con- 
fluence using 0.1% trypsin in 0.02% EDTA (ICN, High 
Wycombe, U.K.) in a ratio of 3:1. All experiments were 
performed using endothelial cells at the third passage 
unless stated otherwise. 
poration was performed using the Biorad electro- 
porator (gene pulser and capacitance extender) under 
a sterile hood (Gelaire BSB, U.K.) at 24°C. 
Following the electroporetic procedure, the endo- 
thelial cells were immediately transferred into fresh 
culture medium and incubated at 37°C. As described 
previously the optimal conditions for electro-transfec- 
tion of endothelial cells were 400 volts; 960btF capaci- 
tance using one electric pulse. ~4 These conditions led 
to a median transfection efficiency of 10%. 
Plasmid DNA 
The plasmid pTCF, which contains a gene for the 
enzyme conferring neomycin resistance, aminoglyco- 
side phosphotransferase (AGPT), is was purified using 
caesium chloride gradient centrifugation. 19 The 
enzyme AGPT is responsible for breaking down G-418 
which inhibits protein synthesis by interfering with 
the codon-anticodon relationship. 2° Endothelial cells 
that incorporate pTCF are able to translate the AGPT 
gene and therefore prevent G-418 from exerting its 
inhibitory actions on protein synthesis. Non-trans- 
fected endothelial cells were to be subjected to the 
toxicity of G-418 and would therefore die when this 
neomycin analogue was added to their culture 
medium. The G-418 was added to the culture medium 
4 days post electroporation o  consecutive days. 
Electroporetic procedure 
Endothelial cells were released from culture flasks 
with trypsin/EDTA and washed with MEM + 5% FCS 
by centrifugation at 300g 4°C for 7 min. Viability was 
assessed by trypan blue exclusion (Sigma, Poole, U.K.) 
using a haemocytometer (Weber, Lancing, U.K.). Via- 
bility was greater than 95% in all cases. Endothelial 
cells at a known concentration were then centrifuged 
(under the same conditions as above) twice; initially 
with 5ml of MEM and subsequently with 10ml of 
phosphate buffered saline (PBS). The final endothelial 
cell pellet was resuspended in 0.8ml of PBS (the 
electroporetic volume), and transferred to a plastic 
cuvette (Biorad, Hemel Hempstead, U.K.). The cuvette 
contained two aluminium electrodes, between which 
the electric discharge passed. The resuspended endo- 
thelial cells were placed between the electrodes and 
were therefore subjected to the electric current as 
required. The capacitance and voltage were selected 
and the plasmid pTCF added at this stage. Electro- 
Measurement ofgrowth rates 
Control endothelial cells (that had not undergone the 
electroporetic procedure) and transfected endothelial 
cells from the same umbilical cord were removed from 
tissue culture flasks using 0.1% trypsin in 0.02% 
EDTA. The cells were washed with MEM + 5% FCS at 
300g for 17 min at 4°C. The resultant cell pellet was 
resuspended ata concentration of i × 104 cells/ml and 
I ml of the resuspension placed per well in a 24 well 
plate (Nunclon, Denmark). The cells were grown until 
confluence. Six wells of control and transfected endo- 
thelial cells were counted daily to determine cell 
number. 
Prostacyclin release by transfected endothelial cells 
Endothelial cells were harvested from an umbilical 
cord as described and placed in a tissue culture flask at 
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37°C. The cells were maintained in tissue culture up to 
passage 3, and then plated in a 24 well plate at a 
concentration of 1 × 105 cells/ml. Transfected endo- 
thelial cells from the same umbilical cord were also 
plated at the same concentration i  24 well plates. 
All cells were incubated for 24 h after which the 
medium was replaced by I ml of plain MEM. Follow- 
ing incubation for a further 30 min, 100~tl of the 
supernatant, representing basal PGI2 release was 
removed. Thrombin was added to the wells to obtain 
a final concentration f 2 units/ml. A further sample 
of medium was taken 10min after the addition of 
thrombin, which was assayed for stimulated PGI2 
release. 
Prostacyclin concentrations in the control and 
transfected samples were assayed by measuring 
6-keto prostaglandin FIR, the stable metabolite ofPGI 2 
breakdown at pH 7.4, using a commercially available 
competitive radioimmunoassay kit (Amersham, U.K.) 
as previously described. 21
Attachment of transfected endothelial cells to ePTFE 
grafts 
(i) Labelling of endothelial cells At confluence, control 
and transfected endothelial cellsfrom the same umbil- 
ical cord, were harvested from culture flasks by 
trypsinisation and neutralised by washing with 
MEM+5% FCS at 300g for 7 mins at 4°C. The 
resultant cell pellet was resuspended to 4 × 106 cells/ 
ml in MEM. 
The cells were labelled with 50~tCi indium 1~ 
oxine (Amersham International, Amersham, U.K.) at 
room temperature for 15 min. 22 After the procedure, 
the cells were washed 3 times with MEM and finally 
resuspended to a final cell concentration of 
1 × 106cells/ml. Labelling efficiency was calculated 
at this stage. 
(ii) Cell attachment Six millimetre xpanded polytetra- 
fluoroethylene (ePTFE - Gore Ltd) vascular prostheses 
were cut into small lengths and opened longitudinally. 
With the lumen uppermost, each portion was placed 
in a well prepared from a modified eppendorf 
tube. 23 
One hundred /~1 of the labelled control and 
transfected ndothelial cell resuspension was added to 
the grafts in each well which were incubated for 30 
min at 37°C in a 5% CO2 and 95% air atmosphere. 
After incubation, the unattached endothelial cells 
were removed by washing theluminal surface three 
times with MEM; all the washings were saved. 
Gamma radioactivity on the graft lumen and 
washings (containing the unattached cells) was deter- 
mined using a LKB-Wallac 1280 UltroGamma II 
counter (LKB-Produkter AB, Sweden). Cell attach- 
ment (CA) was calculated using the following 
formula: 
Total counts on graft 
CA(%) - x 100 
Total counts on washings + Total counts on graft 
Statistical analysis 
Statistical analysis of the results was performed using 
the Minitab Release 8.1 statistical programme (Minitab 
Inc, Pennsylvania, U.S.A.) on a Macintosh LC personal 
computer (Apple Computer Inc, California, U.S.A.). 
The results are presented as median values with 
interquartile ranges where appropriate. Continuous 
variables were analysed using non-parametric 
analysis. 
Results 
Growth rates 
No significant difference was observed between the 
growth rates of control and transfected endothelial 
cells (Fig. 1). The area under each curve was used to 
quantify growth over the 9 day period. Although 
transfected cells displayed a slightly slower growth 
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Fig. 1. Graph illustrating the growth rates of electro-transfected and 
control non-electroporated en othelial cells. Median values are 
shown with interquartile ranges. ([~) transfected; (m) control) 
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rate, this was not significant (W = 100.5, p = 0.76; 
Mann-Whitney U test). 
Prostacyclin release 
Basal and stimulated PGI 2 release by control and 
transduced endothelial cells is illustrated in Fig. 2. 
There was no significant difference in basal PGI 2 
release between transduced and control endothelial 
cells (W = 228.5, p - 0.89). Following thrombin stim- 
ulation, PGI2 release for both control and transduced 
cells was significantly higher than basal PGI2 levels 
(W = 12, p = < 0.001). There was no significant differ- 
ence in the stimulated PGI2 levels for both groups 
(W = 345, p = 0.11; Mann-Whitney U test). 
Cell attachment 
The mean labelling efficiency was 56.8% for control 
and 55.2% for transfected cells. The results (Fig. 3) 
demonstrated that there was no significant difference 
in cell attachment (%) to ePTFE grafts between control 
and transduced endothelial cells (W = 76, p--0.43; 
Mann-Whitney U test). 
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Fig. 2. Graph showing the prostacyclin release by control non- 
electroporated and electro-transfected endothelial cells under basal 
and stimulated conditions. Median values are shown with inter- 
quartile ranges. ([~) control; (~) transfected. 
Discussion 
Endothelial seeding of prosthetic vascular grafts has 
been successful in experimental trials, 24'25 but has not 
had universal success when applied to the clinical 
situation. 26 The relative failure of clinical trials may be 
explained by poor cellular coverage of the graft, 
caused in part by inadequate c ll numbers obtained at 
cell harvest. One method to overcome these difficul- 
ties is to use staged seeding procedures to ensure 
confluent cellular coverage. This technique has 
recently been utilised with encouraging resultsY An 
alternative to staged procedures, which suffer from a 
time lag between cell harvest and graft implantation, 
is to accept sparse cellular coverage, but use recombi- 
nant DNA technology to enhance the anti-thrombotic 
properties of the seeded cells by means of cell 
transfection. The introduction of a gene such as tPA 
may be used to increase the anti-thrombogenicity of a 
seeded endothelial cell surface. 
Foreign genes have been introduced into endo- 
thelial cells by viral and chemical methods. 1-2"5-6 
Electroporation is a physical method of gene transfer 
which has been reported to cause no detrimental 
effects to endothelial cells, s-l° Having successfully 
transfected endothelial cells by electroporation, 14 the 
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Fig. 3. Graph illustrating the attachment (%) of control non- 
electroporated and electro-transfected endothelial cells to ePTFE 
vascular grafts. The data is presented with a bar showing the 
median cell attachment. 
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attachment, replication and prostacyclin secreting 
capacity of the genetically modified endothelial cells 
was compared to a control population of untrans- 
fected endothelial cells. 
Genetically modified endothelial cells must be 
able to replicate rapidly after attachment to any graft 
surface as this would facilitate maximal endothelial 
coverage of the graft and would potentially reduce the 
number of transfected cells used in the seeding 
procedure. In this study, transduced endothelial cells 
exhibited a slower reproductive rate when compared 
with control cells but this was insignificant. 
In the intact arterial wall the endothelium is anti- 
thrombotic due to its anionic charge, the constitutive 
release of EDRF and also to its greatly increased 
prostacyclin release, as Prostacyclin (PGI2) is a highly 
labile arachidonic acid metabolite which is known to 
participate in the regulation of vascular tone and 
thromboresistance. 29 Endothelial cells produce PGI2 in 
large quantities when stimulated, which exhibits 
synergy in action with EDRF, and plays a vital role in 
preventing thrombosis. 29The production of prostacy- 
clin gives a guide to the thromboresistance of ndothe- 
lial monolayers and it was notable that transduced 
endothelium was able to release prostacyclin with 
equal effectiveness to control cells. 
The ability of transfected endothelial cells to 
attach to vascular prostheses i obviously an impor- 
tant requirement when considering transplantation of
endothelial cells. This study demonstrated no sig- 
nificant difference in cell attachment (%) to ePTFE 
grafts between on-transfected and transfected endo- 
thelial cells. This result is very encouraging and paves 
the way forward for further trials of seeding arterial 
and prosthetic surfaces using electro-transfected endo- 
thelial cells. 
This work demonstrates that electro-transfected 
endothelial cells are functionally normal as compared 
with a control endothelial cell population with respect 
to their growth, prostacyclin release and their attach- 
ment to ePTFE prosthetic grafts. These electro-trans- 
fected endothelial cells may potentially be used to 
seed vascular prostheses. 
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